Aventis Savian
Executive Summary
Propentofylline development for Alzheimer's is halted after the Phase IIIb Propentofylline Long-term Use Study demonstrated no difference versus placebo. Aventis was finalizing the protocol for an additional Phase III study in the U.S., slated to begin in early 2000. Aventis' attempt to gain approval in Europe for the glial cell modulator was met with a negative opinion by the Committee for Proprietary Medicinal Products in 1998, which was upheld in 1999 after the company appealed the decision (1"The Pink Sheet" July 26, 1999, p. 18)
You may also be interested in...
Aventis To Continue Cariporide Development In Coronary Artery Bypass
Aventis Pharma will focus its late-stage cariporide development efforts on treating patients undergoing coronary artery bypass grafting, instead of the original indication for acute coronary syndrome, Hoechst Marion Roussel reported in a July 22 announcement on priority pipeline candidates for the merged HMR/Rhone-Poulenc Rorer.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials